Purpose To describe the results of photodynamic therapy (PDT) for juxtapapillary and peripheral retinal capillary hemangioma (RCH). Patients and methods Interventional case series of four eyes (four patients) with juxtapapillary RCH and one eye (one patient) with peripheral RCH. Two eyes with juxtapapillary RCH had received two sessions of full-fluence, double-duration PDT; whereas other two eyes had received single session of half-fluence, single-duration PDT. The peripheral RCH was treated with a single session of full-fluence, single-duration PDT. Results Two patients had von HippelLindau disease. Follow-up duration ranged from 4 months to 1 year. Pre-PDT visual acuity (VA) ranged from 20/200 to HM (juxtapapillary RCH) and 20/100 (peripheral RCH). Among the eyes with juxtapapillary RCH, tumor regression with partial resolution of macular edema was noted in two eyes (one eye each with half-fluence and full-fluence PDT), whereas two eyes had no change in tumor size with persistent macular edema. VA remained stable in three eyes and declined in one eye. In an eye with peripheral RCH, regression of tumor and macular edema with VA improvement was noted. Post-PDT complications included epiretinal membrane (one eye) and transient exudative retinal detachment (one eye). Conclusion PDT can be effective in reducing macular edema associated with RCH but this does not always correspond with an improvement in VA especially for juxtapapillary tumors.
Introduction
Retinal capillary hemangioma (or hemangioblastoma; RCH) is a benign vascular tumor, occurring either as an isolated tumor or as a component of the von Hippel-Lindau (VHL) disease. RCH can be found in the midperipheral retina, juxtapapillary retina, or at the intraneural portion of the optic nerve. Vision loss can occur either from exudation from the tumor causing intraretinal exudates and edema or by glial proliferation causing traction on the retina.
Various treatment options including observation, laser, cryotherapy, radiotherapy, and vitreoretinal surgery have been attempted based on the RCH variant; however, each of these treatment methods has limitations to their use and success rate. 1 Studies using verteporfin photodynamic therapy (PDT) for both juxtapapillary and peripheral RCH have mixed anatomical and functional outcomes. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Post-PDT side effects such as vascular occlusion, optic neuropathy, and tractional retinal detachment (RD) have been reported. More recently, intravitreal anti-vascular endothelial growth factor (VEGF) has been tried but the outcomes are variable. 7, 10, 11 Currently, there is no evidence to suggest that PDT combined with anti-VEGF is superior to PDT alone.
As the optimal management of RCH remains debatable, we present our experience of treating five cases of RCH treated with PDT.
Case reports
Patients were evaluated at the Ocular Oncology Service, Moorfields Eye Hospital, London (ie, patients [1] [2] [3] [4] patients had juxtapapillary RCH, whereas one eye of one patient had peripheral RCH. All patients were treated with verteporfin PDT (Activis, Quantel Medical, Cournon d' Auvergne, France) with a single spot covering the lesion using Area Centralis lens (Volk, Mentor, OH, USA). None of the patients had additional intravitreal injection of either triamcinolone acetonide or anti-VEGF. Table 1 summarizes the patient demographics, clinical characteristics, and PDT treatment strategies and outcomes. Figure 1 shows the patient 2 (a-d) with juxtapapillary RCH, largely remaining unresponsive to two sessions of full-fluence, double-duration PDT and patient 4 (e-h) with juxtapapillary RCH, which had partially responded to the single session of half-fluence PDT. Figure 2 illustrates patient 5 with peripheral RCH highlighting an exudative RD and sub-retinal hemorrhage (b) following PDT treatment, which resolved with time (c).
Discussion
In our series of five eyes with RCH, two different PDT treatment protocols were used for eyes with juxtapapillary RCH, ie., two eyes (patients 1 and 2) had received double-duration, full-fluence PDT, as done previously, 2 whereas two eyes (patients 3 and 4) had received single-duration, half-fluence PDT. Retreatment was done taking under consideration ultrasonographic thickness or the presence of persistent sub-retinal fluid in the macula. This differential/variable PDT protocol did not influence the treatment outcome as one eye each from two protocols had partially resolution of macular edema after PDT treatment. Interestingly, both unresponsive patients were VHL positive. Patients 3 and 4 with juxtapapillary RCH received half-fluence PDT. The rationale for use of half-fluence PDT was to minimize the risk of ischemic optic neuropathy. 2 Of the two patients treated with half-fluence PDT, patient 4 had a more favorable outcome than patient 3. Overall, PDT resulted in an improvement in macular edema in half of the patients with juxtapapillary RCH. However, this does not correspond with an improvement in visual acuity (VA). Singh et al 1 reported that VA rarely improved following treatment if the initial VA is poor (o20/200).
Patient 5 was considered for PDT as it could offer better penetration and reduce the likelihood of extensive hemorrhage. Following treatment, patient had transient exudative RD with an area of sub-retinal hemorrhage and increase in serous detachment of the fovea at 1 week post PDT, possibly representing a reactionary edema to PDT, 6, 9, 12 resulting from change in tumor itself or due to breakdown of blood-retinal barrier. Despite this, there was no exaggerated cicatrical response in our case as observed by other authors. 8 This case is probably representative of a better anatomical and functional outcome following PDT. Though peripheral RCH is thought to be more amenable to treatment due to its peripheral location, complications, such as epiretinal membrane formation and tractional RD can occur.
Anti-VEGF agents were not used in the management of these cases. Even though the VHL-related tumors are thought to be VEGF dependent, these tumors failed to show a consistent response to anti-VEGF therapy, both in the form of monotherapy or in combination with PDT. 7, 10, 11 Thus, the efficacy of the anti-VEGF therapy remains unclear. Although several small studies have described the use of PDT for RCH, the exact reason for 
